Curing Hepatitis C in People Living with HIV in the United States: A Federal, State and Local Collaboration

Publish Date: 
Tuesday, May 28, 2019

Hepatitis C virus (HCV) co-infection affects roughly 25% of people living with HIV (PLWH) in the United States (U.S.).[i]  To effectively combat this epidemic, ongoing provider education has been identified as a key initiative to enhance screening, diagnosis, linkage to care, and treatment of HCV.

Long-Acting Injectable ART: Cabotegravir + Rilpivirine

Publish Date: 
Thursday, April 25, 2019

At CROI 2019, investigators presented 48-week results from the Phase 3 international multisite ATLAS and FLAIR studies of long-acting 2-drug injectable therapy. The study regimen consisted of the integrase inhibitor cabotegravir (CAB) plus the NNRTI rilpivirine (RPV), both given every 4 weeks as intramuscular (IM) injections.

PrEP: TDF/FTC vs TAF/FTC in MSM

Publish Date: 
Thursday, April 25, 2019

TDF/FTC (Truvada) is the only ARV combination currently approved by the FDA for use as preexposure prophylaxis (PrEP). The multinational Phase 3 DISCOVER Study compared the efficacy and safety of TAF/FTC (Descovy) with TDF/FTC, in HIV-uninfected cisgender MSM and transgender women at high risk of sexually acquired HIV.

FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine

Publish Date: 
Friday, April 19, 2019

In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is intended only for adults <--break->who have never received ART and whose HIV has no resistance to either of the two components. It is to be taken once daily without food restrictions.

Immediate ART Initiation: Guide for Clinicians

Susa Coffey's picture
Publish Date: 
Thursday, February 14, 2019

Immediate antiretroviral therapy (ART) refers to starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day the HIV diagnosis is made). This strategy also is known as "rapid ART," "same-day ART," and "treatment upon diagnosis."

Rationale  

Immediate ART initiation may bring earlier benefits in personal health, and earlier reductions in the risk of onward transmission of HIV. For persons with acute infection, immediate ART may limit the HIV viral reservoir.

Short Bites: The Association between Oral Hygiene and Heart Disease

Topic: 
Publish Date: 
Friday, February 1, 2019

The emergence of chronic disease complications in controlled HIV disease has changed the landscape of HIV clinical care. HIV infection confers an increased cardiovascular disease risk which is thought to be due to a complex interplay of mechanistic factors. While traditional cardiovascular risk factors likely play a role, recent evidence suggests that HIV-associated inflammation and immune activation are important mediators of cardiovascular risk.[i]

AETC IPE Programs Prepare the Next Generation of HIV Providers

Publish Date: 
Tuesday, January 15, 2019

Regional AETCs across the United States are working to bring new clinicians into the HIV workforce through inter-professional education (IPE) programs. IPE trains learners in teams in clinical settings where trainees learn from, about, and through each other. One project in Los Angeles is conducting their IPE program through three separate health campuses for nursing (Charles Drew University), medicine (University of California, Los Angeles), and pharmacy (University of Southern California). Cross-posted from TargetHIV coverage of the 2018 National Ryan White Conference

The LATITUDE to Stay On Track: NIH to Launch Study in People Non-Adherent to Daily Treatment

Topic: 
Publish Date: 
Friday, December 7, 2018

weekly pill boxTaking effective HIV medications as prescribed offers many benefits for people living with HIV—life expectancy normalizes and viral loads drop below detectable levels, preventing the risk of sexual transmission in those who achieve and maintain durable viral suppression. Unfortunately, many individuals face significant challenges to adhering to a daily regimen of antiretroviral therapy (ART).

Short Bites: The Association between Oral Disease and Type of Antiretroviral Therapy among Perinatally HIV-Infected Youth

Topic: 
Publish Date: 
Wednesday, December 5, 2018

Antiretroviral therapy (ART) has been very successful at preserving immune function and controlling opportunistic infections among individuals infected with HIV. Oral mucosal diseases associated with advanced immunosuppression, including candidiasis and hairy leukoplakia, are significantly less common among patients on ART.